Experienced in Enlarged Prostate (BPH)

David S. Margel

39 Jabotinski St, 
Petah Tiqwa, M, IL 
Experienced in Enlarged Prostate (BPH)
39 Jabotinski St, 
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

David Margel practices in Petah Tiqwa, Israel. Mr. Margel is rated as an Experienced expert by MediFind in the treatment of Enlarged Prostate (BPH). His top areas of expertise are Prostate Cancer, Male Pattern Baldness, Bladder Cancer, Cystectomy, and Prostatectomy.

His clinical research consists of co-authoring 91 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Enlarged Prostate (BPH).

Gender
Male

Locations

39 Jabotinski St, Petah Tiqwa, M 49100, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial
A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Dietary supplement
Study Phase: Not Applicable
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Device, Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

91 Total Publications

Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure.
Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure.
Journal: Urologic oncology
Published: September 02, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Margel's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile